Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dronabinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 10/20 | 1.00 |
| ▸ | CNR2 | P34972 | 16/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 1.00 |
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 1.00 |
| ▸ | GPR18 | Q14330 | 1/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | HTR1A | P08908 | 1/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.86 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.86 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.86 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronabinol SCHEMBL29390424 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13394311 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL29349828 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL11375978 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL1227386 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL13214137 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL24702729 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL3686519 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL4609 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH | |
| Dronabinol SCHEMBL22705549 | 1.00 | CNR2 (1.00) | CNR2CNR1ABHD12ABHD6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514864-B2 | Compositions and methods for oral administration of cannabinoids | Natural Extraction Systems, LLC (US) | 2026-01-06 | — | — | US | claimed |
| WO-2024194858-A1 | EXTRACELLULAR VESICLES ASSOCIATED WITH CANNABINOID-LIPID CONJUGATES, METHODS FOR PRODUCING THE SAME AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-09-26 | — | — | WO | claimed |
| US-20240269153-A1 | BIOACTIVE BIPHASIC COMPOSITIONS | NATURAL EXTRACTION SYS LLC (US) | 2024-08-15 | — | — | US | claimed |
| EP-4038058-A1 | CANNABINOID DERIVATIVES | Canopy Growth Corporation (CA) | 2022-08-10 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | NATURAL EXTRACTION SYS LLC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260069618-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM GROUP INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12371412-B2 | Methods of preparing cannabinoids or derivatives thereof | FLORASCIENCE INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250214957-A1 | METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOF | FLORASCIENCE INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4565573-A1 | CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST | Salud & Semillas, S.L. (ES) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025101898-A1 | EMULSION COMPRISING AN ACTIVE COMPONENT, AND GUM ACACIA AND LECITHIN AS EMULSIFIERS | BT DE Investments Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4543230-A1 | AEROSOLISABLE FORMULATION | Nicoventures Trading Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| WO-2022251709-A1 | BIOACTIVE BIPHASIC COMPOSITIONS | Natural Extraction Systems, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-4048253-A1 | (-)-CIS TETRAHYDROCANNABINOL ((-)-CIS-THC) FOR USE AS A MEDICAMENT | GW Research Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048254-A1 | (+)-CIS TETRAHYDROCANNABINOL ((+)-CIS-THC) FOR USE AS A MEDICAMENT | GW Research Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
| EP-4038058-A1 | CANNABINOID DERIVATIVES | Canopy Growth Corporation (CA) | 2022-08-10 | — | — | EP | disclosed |
| EP-4017485-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM Group, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022118303-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS, INC. (CA) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022091080-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | SEACH SARID LTD. (IL) | 2022-05-05 | — | — | WO | disclosed |
| CN-114207108-A | Genetically modified host cells producing glycosylated cannabinoids | 奥克塔林生物制剂公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069618-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, IL17A | CNR1 2/4885CNR2 1/4885ABHD12 2315/4885 |
| US-20260083161-A1 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS | CNR2, CNR1, OPRD1 | CNR1 2/4885CNR2 1/4885ABHD12 750/4885 |
| US-20250214957-A1 | METHODS OF PREPARING CANNABINOIDS OR DERIVATIVES THEREOF | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 2158/4885 |
| US-12371412-B2 | Methods of preparing cannabinoids or derivatives thereof | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885ABHD12 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.